Literature DB >> 2402017

Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity.

M J Kelner1, T C McMorris, R Taetle.   

Abstract

Illudins are potent natural products derived from Omphalotus illudens and related fungi. The chemical structure of illudins differs from that of other conventional chemotherapeutic agents. While illudins are toxic to most tumor cells after prolonged exposure (greater than or equal to 48 hr), with shorter exposure times (less than or equal to 2 hr), they show selective toxicity for human myelocytic leukemia and epidermoid, lung, ovarian, and breast carcinoma cells of various species of origin. The apparent histologic specificity of illudin S toxicity is based on an energy-dependent transport mechanism present in sensitive cells, but absent in cells relatively resistant to illudin S. For human myeloid leukemia HL60 cells, the Michaelis constant was 4.2 microM and the maximum velocity was 12.2 pmol/minute per 10 million cells or 730 pmol/hour per 10 million cells. The energy-dependent transport mechanism was detected in other mammalian tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402017     DOI: 10.1093/jnci/82.19.1562

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  17 in total

1.  Chemical and enzymatic reductive activation of acylfulvene to isomeric cytotoxic reactive intermediates.

Authors:  Kathryn E Pietsch; James F Neels; Xiang Yu; Jiachang Gong; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2011-10-14       Impact factor: 3.739

2.  Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues.

Authors:  Xiaodan Liu; Shana J Sturla
Journal:  Mol Biosyst       Date:  2009-07-08

3.  A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Authors:  Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

4.  Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes.

Authors:  Xiaodan Liu; Kathryn E Pietsch; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2011-04-12       Impact factor: 3.739

5.  Acylfulvenes, a new class of potent antitumor agents.

Authors:  T C McMorris; M J Kelner; W Wang; M A Diaz; L A Estes; R Taetle
Journal:  Experientia       Date:  1996-01-16

6.  Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Authors:  F Giles; J Cortes; G Garcia-Manero; S Kornblau; E Estey; M Kwari; A Murgo; H Kantarjian
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.

Authors:  J E Dowell; D H Johnson; J S Rogers; Y Shyr; N McCullough; P Krozely; R F DeVore
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

8.  Up-regulation of human prostaglandin reductase 1 improves the efficacy of hydroxymethylacylfulvene, an antitumor chemotherapeutic agent.

Authors:  Xiang Yu; Melanie M Erzinger; Kathryn E Pietsch; Frances N Cervoni-Curet; John Whang; John Niederhuber; Shana J Sturla
Journal:  J Pharmacol Exp Ther       Date:  2012-08-15       Impact factor: 4.030

9.  A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.

Authors:  A Scott Pierson; Peter Gibbs; Jon Richards; Paul Russ; S Gail Eckhardt; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

10.  Enantioselective total synthesis of (-)-acylfulvene and (-)-irofulven.

Authors:  Dustin S Siegel; Grazia Piizzi; Giovanni Piersanti; Mohammad Movassaghi
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.